Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 4/2009

01-08-2009 | Case Report

A case report suggesting the occurrence of epithelial–mesenchymal transition in obstructive nephropathy

Authors: Tsutomu Inoue, Hirokazu Okada, Tsuneo Takenaka, Yusuke Watanabe, Hiromichi Suzuki

Published in: Clinical and Experimental Nephrology | Issue 4/2009

Login to get access

Abstract

Epithelial–mesenchymal transition (EMT) has been well investigated using cultured kidney epithelial cell lines and the mouse obstructive nephropathy model. The role of EMT in the genesis or progression of human renal fibrosis remains controversial. We report a case of obstructive nephropathy that occurred in a pregnant woman. Renal tissue obtained by percutaneous renal biopsy after the delivery showed marked interstitial fibrosis and obstructive tubuli. Immunofluorescence images clearly demonstrated S100A4-positive tubular epithelial cells in these specimens. With regard to human obstructive nephropathy, this is the first report which proves that tubular epithelial cells become positive for the fibroblast-specific marker. EMT is probably a common event not only in mouse but also in human.
Literature
1.
2.
Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol. 1995;130:393–405.CrossRefPubMed
3.
Ford HL, Silver DL, Kachar B, Sellers JR, Zain SB. Effect of Mts1 on the structure and activity of nonmuscle myosin II. Biochemistry. 1997;36:16321–7.CrossRefPubMed
4.
Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, Kruse C, et al. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem. 2001;276:22699–708.CrossRefPubMed
5.
Kriajevska M, Tarabykina S, Bronstein I, Maitland N, Lomonosov M, Hansen K, et al. Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J Biol Chem. 1998;273:9852–6.CrossRefPubMed
6.
Inoue T, Plieth D, Venkov CD, Xu C, Neilson EG. Antibodies against macrophages that overlap in specificity with fibroblasts. Kidney Int. 2005;67:2488–93.CrossRefPubMed
7.
Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303:848–51.CrossRefPubMed
8.
Rasmussen PE, Nielsen FR. Hydronephrosis during pregnancy: a literature survey. Eur J Obstet Gynecol Reprod Biol. 1988;27:249–59.CrossRefPubMed
9.
Brandes JC, Fritsche C. Obstructive acute renal failure by a gravid uterus: a case report and review. Am J Kidney Dis. 1991;18:398–401.CrossRefPubMed
10.
Jena M, Mitch WE. Rapidly reversible acute renal failure from ureteral obstruction in pregnancy. Am J Kidney Dis. 1996;28:457–60.CrossRefPubMed
11.
Chevalier RL. Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol. 2006;2:157–68.CrossRefPubMed
12.
Kaneto H, Ohtani H, Fukuzaki A, Ishidoya S, Takeda A, Ogata Y, et al. Increased expression of TGF-beta1 but not of its receptors contributes to human obstructive nephropathy. Kidney Int. 1999;56:2137–46.CrossRefPubMed
13.
Nishitani Y, Iwano M, Yamaguchi Y, Harada K, Nakatani K, Akai Y, et al. Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int. 2005;68:1078–85.CrossRefPubMed
14.
Rossini M, Cheunsuchon B, Donnert E, Ma LJ, Thomas JW, Neilson EG, et al. Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int. 2005;68:2621–8.CrossRefPubMed
15.
Gibbs FE, Barraclough R, Platt-Higgins A, Rudland PS, Wilkinson MC, Parry EW. Immunocytochemical distribution of the calcium-binding protein p9Ka in normal rat tissues: variation in the cellular location in different tissues. J Histochem Cytochem. 1995;43:169–80.CrossRefPubMed
16.
Djamali A, Vidyasagar A, Adulla M, Hullett D, Reese S. Nox-2 is a modulator of fibrogenesis in kidney allografts. Am J Transplant. 2009;9:74–82.CrossRefPubMed
Metadata
Title
A case report suggesting the occurrence of epithelial–mesenchymal transition in obstructive nephropathy
Authors
Tsutomu Inoue
Hirokazu Okada
Tsuneo Takenaka
Yusuke Watanabe
Hiromichi Suzuki
Publication date
01-08-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0168-4

Other articles of this Issue 4/2009

Clinical and Experimental Nephrology 4/2009 Go to the issue

Original Article

Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker

Review Article

Current status and issues of C1q nephropathy

Case Report

Acute pancreatitis with CMV papillitis and cholangiopathy in a renal transplant recipient

Original Article

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: unusual clinical associations and novel claudin16 mutation in an Egyptian family

Original Article

Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients

Review Article

Nocturnal hemodialysis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits